Thomas N K, Wright R A, Howson P A, Kingston A E, Schoepp D D, Jane D E
Department of Pharmacology, School of Medical Sciences, University of Bristol, BS8 1TD, Bristol, UK.
Neuropharmacology. 2001 Mar;40(3):311-8. doi: 10.1016/s0028-3908(00)00169-6.
(S)-3,4-Dicarboxyphenylglycine (DCPG) has been tested on cloned human mGlu1-8 receptors individually expressed in AV12-664 cells co-expressing a rat glutamate/aspartate transporter and shown to be a potent and selective mGlu8a receptor agonist (EC(50) value 31+/-2 nM, n=3) with weaker effects on the other cloned mGlu receptors (EC(50) or IC(50) values >3.5 microM on mGlu1-7). Electrophysiological characterisation on the neonatal rat spinal cord preparation revealed that (S)-3,4-DCPG depressed the fast component of the dorsal root-evoked ventral root potential (fDR-VRP) giving a biphasic concentration-response curve showing EC(50) values of 1.3+/-0.2 microM (n=17) and 391+/-81 microM (n=17) for the higher and lower affinity components, respectively. The receptor mediating the high-affinity component was antagonised by 200 microM (S)-alpha-methyl-2-amino-4-phosphonobutyrate (MAP4, K(D) value 5.4+/-1.5 microM (n=3)), a group III metabotropic glutamate (mGlu) receptor antagonist. The alpha-methyl substituted analogue of (S)-3,4-DCPG, (RS)-3,4-MDCPG (100 microM), antagonised the effects of (S)-3,4-DCPG (K(D) value 5.0+/-0.4 microM, n=3) in a similar manner to MAP4. (S)-3,4-DCPG-induced depressions of the fDR-VRP in the low-affinity range of the concentration-response curve were potentiated by 200 microM (S)-alpha-ethylglutamate (EGLU), a group II mGlu receptor antagonist, and were relatively unaffected by MAP4 (200 microM). However, depressions of the fDR-VRP mediated by the AMPA selective antagonist (R)-3,4-DCPG were not potentiated by EGLU, suggesting that the low-affinity component of the concentration-response curve for (S)-3,4-DCPG is not due to antagonism of postsynaptic AMPA receptors. It is suggested that the receptor responsible for mediating the high-affinity component is mGlu8. The receptor responsible for mediating the low-affinity effect of (S)-3,4-DCPG has yet to be identified but it is unlikely to be one of the known mGlu receptors present on primary afferent terminals or an ionotropic glutamate receptor of the AMPA or NMDA subtype.
(S)-3,4-二羧基苯基甘氨酸(DCPG)已在单独表达于共表达大鼠谷氨酸/天冬氨酸转运体的AV12-664细胞中的克隆人mGlu1-8受体上进行了测试,结果显示它是一种强效且选择性的mGlu8a受体激动剂(半数有效浓度(EC(50))值为31±2 nM,n = 3),对其他克隆的mGlu受体的作用较弱(对mGlu1-7的EC(50)或半数抑制浓度(IC(50))值>3.5 μM)。对新生大鼠脊髓标本的电生理学特性研究表明,(S)-3,4-DCPG抑制背根诱发腹根电位的快速成分(fDR-VRP),给出双相浓度-反应曲线,高亲和力成分和低亲和力成分的EC(50)值分别为1.3±0.2 μM(n = 17)和391±81 μM(n = 17)。介导高亲和力成分的受体被200 μM的(S)-α-甲基-2-氨基-4-膦酰丁酸(MAP4,解离常数(K(D))值为5.4±1.5 μM,n = 3)拮抗,MAP4是一种III组代谢型谷氨酸(mGlu)受体拮抗剂。(S)-3,4-DCPG的α-甲基取代类似物(RS)-3,4-MDCPG(100 μM)以与MAP4相似的方式拮抗(S)-3,4-DCPG的作用(K(D)值为5.0±0.4 μM,n = 3)。在浓度-反应曲线的低亲和力范围内,(S)-3,4-DCPG诱导的fDR-VRP抑制被200 μM的(S)-α-乙基谷氨酸(EGLU)增强,EGLU是一种II组mGlu受体拮抗剂,并且相对不受MAP4(200 μM)的影响。然而,AMPA选择性拮抗剂(R)-3,4-DCPG介导的fDR-VRP抑制未被EGLU增强,这表明(S)-3,4-DCPG浓度-反应曲线的低亲和力成分不是由于对突触后AMPA受体的拮抗作用。提示介导高亲和力成分的受体是mGlu8。介导(S)-3,4-DCPG低亲和力效应的受体尚未确定,但不太可能是初级传入终末上存在的已知mGlu受体之一或AMPA或NMDA亚型的离子型谷氨酸受体。